Gemini Therapeutics (NASDAQ:GMTX – Get Free Report) and Collegium Pharmaceutical (NASDAQ:COLL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability and analyst recommendations.
This is a summary of recent recommendations for Gemini Therapeutics and Collegium Pharmaceutical, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Collegium Pharmaceutical has a consensus price target of $35.50, indicating a potential upside of 56.73%. Given Collegium Pharmaceutical’s higher possible upside, analysts clearly believe Collegium Pharmaceutical is more favorable than Gemini Therapeutics.
Insider and Institutional Ownership
Risk & Volatility
Gemini Therapeutics has a beta of -0.12, suggesting that its stock price is 112% less volatile than the S&P 500. Comparatively, Collegium Pharmaceutical has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
This table compares Gemini Therapeutics and Collegium Pharmaceutical’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings and Valuation
This table compares Gemini Therapeutics and Collegium Pharmaceutical’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Gemini Therapeutics||N/A||N/A||-$71.87 million||($1.00)||-1.35|
|Collegium Pharmaceutical||$463.93 million||1.70||-$25.00 million||($0.37)||-61.21|
Collegium Pharmaceutical has higher revenue and earnings than Gemini Therapeutics. Collegium Pharmaceutical is trading at a lower price-to-earnings ratio than Gemini Therapeutics, indicating that it is currently the more affordable of the two stocks.
Collegium Pharmaceutical beats Gemini Therapeutics on 8 of the 12 factors compared between the two stocks.
About Gemini Therapeutics
Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.